A multimodality approach to localized rectal cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Cervantes, A ^a   Chirivella, I ^a   Rodriguez Braun, E ^a   Campos, S ^a   Navarro, S ^a   Garcia Granero E ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; ECHOGRAPHY; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RADIATION DOSE FRACTIONATION; RECTUM CANCER; SURGICAL TECHNIQUE;

COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS;

EID: 33749632740     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl250     Document Type: Article

References (47)

1. Department of Health, UK. Topic 2B. Colorectal multidisciplinary team. In: Manual for Cancer Services, 2004.
2. Madoff RG. Chemoradiotherapy for rectal cancer-When, Why and How? N Eng J Med 2004; 351: 1790-1792.
3. Nagtegaal ID, van de Velde CJH, van der Worp E et al. Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J Clin Oncol 2002; 20: 1729-1734.
4. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26: 350-357.
5. Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89: 327-334.
6. García-Aguilar J, Pollack J, Lee SH et al. Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 2002; 45: 10-15.
7. Mackay SG, Pager CK, Joseph D et al. Assessment of accuracy of transrectal ultrasonography in anorectal neoplasia. Br J Surg 2003; 90: 346-350.
8. Beets-Tan RG, Beets GL. Rectal cancer: Review with emphasis on MR imaging. Radiology 2004; 232: 335-346.
9. Brown G, Radcliffe AG, Newcombe RG et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003; 90: 355-364.
10. Burton S, Brown G, Daniels IR et al. MRI directed multidisciplinary team preoperative treatment strategy: The way to eliminate positive circumferential margins' Br J Cancer 2006; 94: 351-357.
11. Wibe A, Møller B, Norstein J et al. A national strategy change in treatment policy for rectal cancer - Implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857-866.
12. Lehander Martling A, Holm T, Rutqvist LE et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Lancet 2000; 356: 93-96.
13. Kapiteijn E, Marijnen CAM, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
14. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 2003; 4: 695-702.
15. Nagtegaal ID, van de Velde CJH, Marijnen CAM et al. Low Rectal Cancer: A Call for a Change of Approach in Abdominoperineal Resection. J Clin Oncol 2005; 36: 9257-9264.
16. Birbeck KF, Macklin CP, Tiffin NJ et al. Rates of circumferential margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002; 235: 449-457.
17. http://vww.virtualpathology.leeds.ac.uk.
18. Quirke P. Optimal management of rectal cancer. The role of the pathologists. Eur J Cancer Suppl 2003; 3: 351-359.
19. Dworak O, Keilholtz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
20. Bouzourene H, Bosman FT, Seelentag W et al. Importance of tumor regression assessment in predicting the outcome in patents with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2000; 94: 1121-1130.
21. Wheeler JM, Warren BF, Mortensen NJ et al. Quantification of histologic regression of rectal cancer after irradiation: A proposal for a modified staging system. Dis Colon Rectum 2002; 45: 1051-1056.
22. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
23. Mawdsley S, Glynne-Jones R, Grainger J et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005; 63: 745-752.
24. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncologica 2003; 42: 476-492.
25. Swedish rectal cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Eng J Med 1997; 336: 980-987.
26. Folkesson J, Birgisson H, Påhlman L et al. The Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate, J Clin Oncol 2005; 23: 5644-5650.
27. Marijnen CAM, Nagtegaal ID, Klein Kranenbarg E et al, No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984.
28. van den Brink M, Stiggelbout AM, van den Hout WB et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 2004; 22: 3958-3964.
29. Marijnen CAM, Nagtegaal ID, Kapiteijn E et al: Radiotherapy does not compensate for positive resection margins in rectal cancer patents. Int J Radiat Oncol Biol Phys 2003; 55: 1311-1320.
30. Peeters KCMJ, van de Velde CJH, Leer JWH et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients - A Dutch Colorectal Cancer Group Study. J Clin Oncol 2005; 23: 6199-6206.
31. Marijnen CA, Kapiteijn E, van de Velde CJH et al: Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20: 817-825.
32. Marijnen CA, van de Velde CJH, Putter H et al: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847-1858.
33. Birgisson H, Påhlman L, Gunnarsson U, Gilmelius B. Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23: 8697-8705.
34. Bujko K, Nowacki MP, Naslerowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004; 72: 15-24.
35. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 2004; 22: 1785-1796.
36. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
37. Bosset JF, Calals G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results - EORTC 22921. J Clin Oncol 2005; 23: 5620-5627.
38. Bosset JF, Calais G, Mineur L et al. Preoperative radiation in rectal cancer: Effect and timing of additional chemotherapy. 5 year results of the EORTC 22921 trial. J Clin Oncol 2005; 23 (Suppl 16S): 3505 (abstract).
39. Gerard JP, Bonnetain F, Conroy T et al. Preoperative radiotherapy + 5-FU/ folinic acid in T3-4 rectal cancers: Results of the FFCD 9203 randomized trial. J Clin Oncol 2005; 23 (Suppl 16S): 3504 (abstract).
40. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
41. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
42. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients wiih metastatic colorectal cancer, J Clin Oncol 2004; 22: 2084-2091.
43. Glynne-Jones R, Dunst J, and Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: How successful have we been? Ann Oncol 2006; 17: 361-367.
44. Machiels JP, Duck L, Honhon B et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patents with rectal cancer: The RadiOxCape study. Ann Oncol 2005; 16: 1898-1905.
45. Glynne-Jones R, Sebag-Montefiore D, Maugahn TS et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) In patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-56.
46. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
47. Glynne-Jones R, Grainger J, Harrison M et al, Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 2006; 94: 363-371.